ZT ZTS Zoetis Loading... : Investor Sentiment and Bull/Bear Views

Zoetis has consistently grown sales year-over-year and maintains high profitability, which historically supports higher stock prices. If the market is overly focused on temporary headwinds (patent cliffs, debt), the stock may be mispriced relative to its stable cash generation. Author sees a long-term value opportunity, but the trade relies on the market eventually re-rating the stock once fears fade. Apoquel patent expiry (2025), Simparica expiry (2027), high debt load, weak consumer willingness to pay premium pet med prices, and lack of blockbuster pipeline replacements.

Gabrail describes Burry's bullish basket of cheap, beaten-down, unloved companies that the market ignored while chasing AI: Lululemon, PayPal, Fiserv, Zoetis, Mercado Libre, Flutter, JD.com, Tencent, Adobe, Fannie Mae, and Freddie Mac. The rationale is classic value investing—real or profitable businesses trading at discounts because they are no longer exciting; some, like PayPal and JD.com, rallied sharply.

Michael Burry is buying Zoetis, the global leader in pet medications. The stock has collapsed 50% due to temporary consumer pressure reducing vet visits, but underlying pet ownership trends remain strong (more pets than children). The business is recurring, and the valuation is at historical lows of 10-11x earnings versus a normal 30x. Even zero growth would likely produce positive returns; any recovery would amplify gains.